Johnson Investment Counsel Inc. Invests $168,000 in NeoGenomics, Inc. (NASDAQ:NEO)

Johnson Investment Counsel Inc. acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO) during the 4th quarter, HoldingsChannel reports. The firm acquired 10,206 shares of the medical research company’s stock, valued at approximately $168,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Nordea Investment Management AB raised its position in shares of NeoGenomics by 2.8% in the fourth quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company’s stock valued at $1,301,000 after purchasing an additional 2,125 shares during the period. Geode Capital Management LLC raised its holdings in NeoGenomics by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company’s stock valued at $45,022,000 after acquiring an additional 36,136 shares during the period. Jennison Associates LLC lifted its position in shares of NeoGenomics by 4.7% during the third quarter. Jennison Associates LLC now owns 1,276,468 shares of the medical research company’s stock worth $18,828,000 after acquiring an additional 57,041 shares in the last quarter. Algert Global LLC lifted its position in shares of NeoGenomics by 204.3% during the third quarter. Algert Global LLC now owns 79,983 shares of the medical research company’s stock worth $1,180,000 after acquiring an additional 53,700 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of NeoGenomics by 2.4% in the fourth quarter. Rhumbline Advisers now owns 389,003 shares of the medical research company’s stock worth $6,411,000 after acquiring an additional 9,098 shares during the period. 98.50% of the stock is owned by institutional investors.

NeoGenomics Price Performance

NEO stock opened at $9.82 on Friday. The firm has a 50 day simple moving average of $13.11 and a two-hundred day simple moving average of $14.81. The stock has a market cap of $1.26 billion, a PE ratio of -15.84 and a beta of 1.28. NeoGenomics, Inc. has a one year low of $8.98 and a one year high of $19.12. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The company had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $173.40 million. On average, analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Piper Sandler decreased their price objective on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Jefferies Financial Group initiated coverage on NeoGenomics in a research report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price target on the stock. Needham & Company LLC cut their price objective on shares of NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Benchmark lowered shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, The Goldman Sachs Group cut their price target on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, NeoGenomics has an average rating of “Moderate Buy” and a consensus price target of $19.60.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.